FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2276528744> ?p ?o ?g. }

• W2276528744 endingPage "8362" @default.
• W2276528744 startingPage "8350" @default.
• W2276528744 abstract "Multiple myeloma is an aggressive hematopoietic cancer of plasma cells. The recent emergence of three effective FDA-approved proteasome-inhibiting drugs, bortezomib (Velcade®), carfilzomib (Kyprolis®), and ixazomib (Ninlaro®), confirms that proteasome inhibitors are therapeutically useful against neoplastic disease, in particular refractory multiple myeloma and mantle cell lymphoma. This study describes the synthesis, computational affinity assessment, and preclinical evaluation of TIR-199, a natural product-derived syrbactin structural analog. Molecular modeling and simulation suggested that TIR-199 covalently binds each of the three catalytic subunits (β1, β2, and β5) and revealed key interaction sites. In vitro and cell culture-based proteasome activity measurements confirmed that TIR-199 inhibits the proteasome in a dose-dependent manner and induces tumor cell death in multiple myeloma and neuroblastoma cells as well as other cancer types in the NCI-60 cell panel. It is particularly effective against kidney tumor cell lines, with >250-fold higher anti-tumor activities than observed with the natural product syringolin A. In vivo studies in mice revealed a maximum tolerated dose of TIR-199 at 25 mg/kg. The anti-tumor activity of TIR-199 was confirmed in hollow fiber assays in mice. Adverse drug reaction screens in a kidney panel revealed no off-targets of concern. This is the first study to examine the efficacy of a syrbactin in animals. Taken together, the results suggest that TIR-199 is a potent new proteasome inhibitor with promise for further development into a clinical drug for the treatment of multiple myeloma and other forms of cancer. Multiple myeloma is an aggressive hematopoietic cancer of plasma cells. The recent emergence of three effective FDA-approved proteasome-inhibiting drugs, bortezomib (Velcade®), carfilzomib (Kyprolis®), and ixazomib (Ninlaro®), confirms that proteasome inhibitors are therapeutically useful against neoplastic disease, in particular refractory multiple myeloma and mantle cell lymphoma. This study describes the synthesis, computational affinity assessment, and preclinical evaluation of TIR-199, a natural product-derived syrbactin structural analog. Molecular modeling and simulation suggested that TIR-199 covalently binds each of the three catalytic subunits (β1, β2, and β5) and revealed key interaction sites. In vitro and cell culture-based proteasome activity measurements confirmed that TIR-199 inhibits the proteasome in a dose-dependent manner and induces tumor cell death in multiple myeloma and neuroblastoma cells as well as other cancer types in the NCI-60 cell panel. It is particularly effective against kidney tumor cell lines, with >250-fold higher anti-tumor activities than observed with the natural product syringolin A. In vivo studies in mice revealed a maximum tolerated dose of TIR-199 at 25 mg/kg. The anti-tumor activity of TIR-199 was confirmed in hollow fiber assays in mice. Adverse drug reaction screens in a kidney panel revealed no off-targets of concern. This is the first study to examine the efficacy of a syrbactin in animals. Taken together, the results suggest that TIR-199 is a potent new proteasome inhibitor with promise for further development into a clinical drug for the treatment of multiple myeloma and other forms of cancer." @default.
• W2276528744 created "2016-06-24" @default.
• W2276528744 creator A5001330835 @default.
• W2276528744 creator A5002482218 @default.
• W2276528744 creator A5032380209 @default.
• W2276528744 creator A5034835492 @default.
• W2276528744 creator A5039810760 @default.
• W2276528744 creator A5056401842 @default.
• W2276528744 creator A5064171074 @default.
• W2276528744 creator A5081191243 @default.
• W2276528744 date "2016-04-01" @default.
• W2276528744 modified "2023-10-16" @default.
• W2276528744 title "Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death" @default.
• W2276528744 cites W1481321944 @default.
• W2276528744 cites W150727265 @default.
• W2276528744 cites W1549357029 @default.
• W2276528744 cites W1964602059 @default.
• W2276528744 cites W1970349229 @default.
• W2276528744 cites W1992978957 @default.
• W2276528744 cites W2001372552 @default.
• W2276528744 cites W2003698928 @default.
• W2276528744 cites W2006845846 @default.
• W2276528744 cites W2019168676 @default.
• W2276528744 cites W2023366550 @default.
• W2276528744 cites W2024475252 @default.
• W2276528744 cites W2025549843 @default.
• W2276528744 cites W2037569459 @default.
• W2276528744 cites W2042171909 @default.
• W2276528744 cites W2061215798 @default.
• W2276528744 cites W2064976423 @default.
• W2276528744 cites W2067653691 @default.
• W2276528744 cites W2071430789 @default.
• W2276528744 cites W2072117786 @default.
• W2276528744 cites W2078114300 @default.
• W2276528744 cites W2082140471 @default.
• W2276528744 cites W2083343710 @default.
• W2276528744 cites W2084951981 @default.
• W2276528744 cites W2087312216 @default.
• W2276528744 cites W2102961664 @default.
• W2276528744 cites W2104599023 @default.
• W2276528744 cites W2105668062 @default.
• W2276528744 cites W2108063064 @default.
• W2276528744 cites W2108235071 @default.
• W2276528744 cites W2108608653 @default.
• W2276528744 cites W2111650326 @default.
• W2276528744 cites W2118233996 @default.
• W2276528744 cites W2124560610 @default.
• W2276528744 cites W2127758731 @default.
• W2276528744 cites W2130314846 @default.
• W2276528744 cites W2141528038 @default.
• W2276528744 cites W2147422161 @default.
• W2276528744 cites W2147993766 @default.
• W2276528744 cites W2150085746 @default.
• W2276528744 cites W2153716391 @default.
• W2276528744 cites W2154308017 @default.
• W2276528744 cites W2156879354 @default.
• W2276528744 cites W2321987807 @default.
• W2276528744 cites W4211135634 @default.
• W2276528744 cites W608555576 @default.
• W2276528744 cites W941989909 @default.
• W2276528744 doi "https://doi.org/10.1074/jbc.m115.710053" @default.
• W2276528744 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4861411" @default.
• W2276528744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26907687" @default.
• W2276528744 hasPublicationYear "2016" @default.
• W2276528744 type Work @default.
• W2276528744 sameAs 2276528744 @default.
• W2276528744 citedByCount "14" @default.
• W2276528744 countsByYear W22765287442016 @default.
• W2276528744 countsByYear W22765287442018 @default.
• W2276528744 countsByYear W22765287442019 @default.
• W2276528744 countsByYear W22765287442020 @default.
• W2276528744 countsByYear W22765287442021 @default.
• W2276528744 countsByYear W22765287442022 @default.
• W2276528744 countsByYear W22765287442023 @default.
• W2276528744 crossrefType "journal-article" @default.
• W2276528744 hasAuthorship W2276528744A5001330835 @default.
• W2276528744 hasAuthorship W2276528744A5002482218 @default.
• W2276528744 hasAuthorship W2276528744A5032380209 @default.
• W2276528744 hasAuthorship W2276528744A5034835492 @default.
• W2276528744 hasAuthorship W2276528744A5039810760 @default.
• W2276528744 hasAuthorship W2276528744A5056401842 @default.
• W2276528744 hasAuthorship W2276528744A5064171074 @default.
• W2276528744 hasAuthorship W2276528744A5081191243 @default.
• W2276528744 hasBestOaLocation W22765287441 @default.
• W2276528744 hasConcept C150903083 @default.
• W2276528744 hasConcept C185592680 @default.
• W2276528744 hasConcept C203014093 @default.
• W2276528744 hasConcept C207001950 @default.
• W2276528744 hasConcept C27740335 @default.
• W2276528744 hasConcept C2776364478 @default.
• W2276528744 hasConcept C2777478702 @default.
• W2276528744 hasConcept C2778367456 @default.
• W2276528744 hasConcept C2780108899 @default.
• W2276528744 hasConcept C2781098529 @default.
• W2276528744 hasConcept C502942594 @default.
• W2276528744 hasConcept C54355233 @default.
• W2276528744 hasConcept C55493867 @default.
• W2276528744 hasConcept C71924100 @default.

• next